Disney Matthew D
Department of Chemistry, The Scripps Research Institute, 130 Scripps Way #3A1, Jupiter, FL 33458, USA.
Drug Discov Today. 2013 Dec;18(23-24):1228-36. doi: 10.1016/j.drudis.2013.07.024. Epub 2013 Aug 9.
RNA is an important yet vastly underexploited target for small molecule chemical probes or lead therapeutics. Small molecules have been used successfully to modulate the function of the bacterial ribosome, viral RNAs and riboswitches. These RNAs are either highly expressed or can be targeted using substrate mimicry, a mainstay in the design of enzyme inhibitors. However, most cellular RNAs are neither highly expressed nor have a lead small molecule inhibitor, a significant challenge for drug discovery efforts. Herein, I describe the design of small molecules targeting expanded repeating transcripts that cause myotonic muscular dystrophy (DM). These test cases illustrate the challenges of designing small molecules that target RNA and the advantages of targeting repeating transcripts. Lastly, I discuss how small molecules might be more advantageous than oligonucleotides for targeting RNA.
RNA是小分子化学探针或先导治疗药物的一个重要但尚未得到充分利用的靶点。小分子已成功用于调节细菌核糖体、病毒RNA和核糖开关的功能。这些RNA要么高度表达,要么可以通过底物模拟来靶向,这是酶抑制剂设计的主要方法。然而,大多数细胞RNA既不高度表达,也没有先导小分子抑制剂,这对药物研发工作来说是一个重大挑战。在此,我描述了针对导致强直性肌营养不良(DM)的扩展重复转录本的小分子设计。这些测试案例说明了设计靶向RNA的小分子所面临的挑战以及靶向重复转录本的优势。最后,我讨论了小分子在靶向RNA方面可能比寡核苷酸更具优势的原因。